The Five Trends Defining Biotech Financing in 2026
There is much more money available for biopharma and life sciences in Europe than there was almost two decades ago.”
Justin Stindt Consultants Welcomes Javier Arribas as Equity Partner
We are delighted to announce that Javier Arribas has been promoted to Partner at Justin Stindt Consultants, joining the firm
PICO Anticipation: A Critical Activity Ahead of JCA
The European Commission has recently announced that the first Joint Clinical Assessment (JCA) is finalised and undergoing final checks prior
The #1 Biotech Misconception About Market Access: “A Partner Will Handle It”
“We don’t need to worry about Market Access, once we find a partner, they’ll take care of it.” It is
2026 Most-Favoured-Nation Playbook: Everything We Know About the Bilateral Drug Pricing Deals
In less than twelve months, the Trump administration turned a contested policy idea into a structural reality across the pharmaceutical
CMS GUARD Model 2026: A Complete Guide for Pharma and Biotech
December 2025 marked a defining moment in U.S. drug pricing and Medicare reimbursement policy. Alongside the GLOBE Model for Medicare